Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from EMD Serono, Inc. and Pfizer, Inc.
Adjuvant Therapy in Urothelial Carcinoma (UC)
In advanced or metastatic UC a heavily cytotoxic “sledgehammer” approach has traditionally been used. Platinum-based chemotherapy is still the preferred first-line approach. But this non-specific cytotoxic treatment is often intolerable for the typically older UC patient. Until recently, there were no second-line options beyond the chemotherapeutic sledgehammer. Today, treatments with more selective mechanisms of action take advantage of fresh translational insights into UC. These novel therapeutics offer more efficient targeting for patients who have run out of options. But for clinicians, the introduction of these agents complicates an already complex condition. This activity will guide them in selecting and using these options.
This is a Twitter-based tutorial designed to provide key information in an accessible format and location.
Petros Grivas, MD, PhD
Dept. of Medicine, Division of Medical Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Brian Rini, MD, FASCO
Chief of Clinical Trials
Vanderbilt-Ingram Cancer Center
Ingram Professor of Medicine
Department of Hematology/Oncology
Vanderbilt University Medical Center
This educational initiative has been designed for genitourinary oncologists, medical oncologists, surgical oncologists, radiologists, urologists, nurse practitioners (NPs), physician assistants (PAs), clinical nurse specialists (CNSs), advanced practice nurses (APNs), oncology clinical nurses (OCNs), and clinical oncology pharmacists (BCOPs) involved in the care and coordination of patients with UC.
Upon completion of this educational activity, participants should be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of July 20, 2021 through July 20, 2022, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Physician Continuing Education Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Integrity Continuing Education designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or firstname.lastname@example.org.
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Petros Grivas, MD, PhD
Consulting fees: 4D Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Clovis Oncology, Dyania Health, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech/Roche, Genzyme, GlaxoSmithKline, Guardant, Heron Therapeutics, Immunomedics/Gilead, Infinity Pharmaceuticals, Janssen, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics, Regeneron Pharmaceuticals, Seattle Genetics
Institutional research funding: Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm, EMD Serono, GlaxoSmithKline, Immunomedics, Kure It Cancer Research, Merck, Mirati Therapeutics, Pfizer, QED Therapeutics
Brian Rini, MD
Research Funding to Institution: Aravive, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Dragonfly Therapeutics, Exelixis, Hoffman-LaRoche, Immunomedics, Incyte, Mirati Therapeutics, Merck, Pfizer, Seattle Genetics, Surface Oncology, Taris
Consulting: 3DMedicines, Aravive, Alkermes, Arrowhead, Aveo, Bristol Myers Squibb, Compugen, Corvus, Eisai, GlaxoSmithKline, Genentech/Roche, Merck, Pfizer, Shionogi, Surface Oncology, Synthorx
Stock: PTC Therapeutics
The Integrity Continuing Education planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer below 8 is not recommended
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.